Key Takeaways Dry mouth, bad breath, and taste changes can happen with semaglutide or tirzepatide, though there's no solid clinical proof that the medication directly causes them
IFG, impaired fasting glucose
Typically, individuals on Exenatide see a modest reduction in weight of about 3-5%, which is relatively minor when juxtaposed with alternative GLP-1 receptor agonists
Tirzepatide and retatrutide, which have dual agonist activities targeting both GLP-1 receptor and GIP receptor (GIPR) or GLP-1 receptor and glucagon receptor (GCGR), respectively, have been shown to improve energy expenditure and metabolic flexibility in other studies [50, 51]
Most of these symptoms improve over time as the body adjusts
Back Capozzi, ME, DiMarchi, RD, Tschp, MH, et al (13 June 2019) Targeting the incretin/glucagon system with triagonists to treat diabetes', Endocrine Reviews , 39/5, 719-38